{
    "clinical_study": {
        "@rank": "104089", 
        "acronym": "ARTIST-II", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "S-1 40-60mg BID (4weeks - 2weeks off) x 8 cycles"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "{S-1 40mg/m2 BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 week} x 8 cycles"
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Active Comparator", 
                "description": "{S-1 40mg/m2 BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 2 cycles \u2192 S-1 40mg BID (2weeks - 1week off - 2weeks)+ RT 45 Gy (5weeks) \u2192 Rest for 4 weeks \u2192 {S-1 40mg/m2 BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 4 cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "The optimal regimen for adjuvant treatment has not been established in GC yet. We plan to\n      compare TS-1, TS-1/oxaliplatin with or without RT in D2 resected gastric cancer."
        }, 
        "brief_title": "Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin \u00b1 Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial", 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically proven gastric or gastroesophageal adenocarcinoma\n\n          2. \u2265 D2 lymph node dissection, curative gastrectomy\n\n          3. Stage II, III (AJCC 2010) with any N (any stage with N0 will be excluded)\n\n          4. Age  > 19\n\n          5. ECOG 0-2\n\n          6. No distant metastasis\n\n          7. Adequate bone marrow functions (ANC \u2265 1,500/ul, blood platelet \u2265 100,000/ul,\n             haemoglobin \u2265 10g/dl,  transfusion allowed)\n\n          8. Adequate renal functions(serum creatinine \u2264 1.5mg/dl)\n\n          9. liver functions (serum bilirubin \u2264 1.5mg/dl, AST/ALT \u2264 3 times(normal value)\n\n         10. Written informed consent\n\n         11. Possible oral intake (food, drug)\n\n        Exclusion Criteria:\n\n          -  Subjects presenting with any of the following will not be included in the study\n\n               1. Active infection requiring antibiotics\n\n               2. Pregnant, lactating women\n\n               3. Concurrent systemic illness not appropriate for chemotherapy\n\n               4. Resection margin (+) at permanent pathology\n\n               5. Pathologic stage I or IV (Ia or Ib according to AJCC 2010)\n\n               6. Inadequate surgery including D0, D1 resection, dissected LNs  less than 12\n\n               7. Paraaortic lymph node (+), pathologically proven\n\n               8. women of potential childbearing not employing adequate contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761461", 
            "org_study_id": "2012-06-061"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A", 
                "Arm B", 
                "Arm C"
            ], 
            "intervention_name": "TS-1, oxaliplatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Oxaliplatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 26, 2013", 
        "location": {
            "contact": {
                "email": "hyejin1217.jang@samsung.com", 
                "last_name": "Hyejin Jang, RN", 
                "phone": "3410-6859"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "hyejin1217.jang@samsung.com", 
            "last_name": "Hyejin Jang, RN", 
            "phone": "3410-6859"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary endpoint of the study is disease-free survival (DFS).", 
            "safety_issue": "Yes", 
            "time_frame": "3-year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761461"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Won Ki Kang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}